Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridone C-1305, a topoisomerase II inhibitor with antitumor activities

Nucleic Acids Research

Volumn 33, Issue 18, 2005, Pages 6034-6047

  Lemke, Krzysztof ^a,d   Wojciechowski, Marcin ^a   Laine, William ^b   Bailly, Christian ^b,e   Colson, Pierre ^c   Baginski, Maciej ^a   Larsen, Annette K ^d   Skladanowski, Andrzej ^a  

^a GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

^b CENTRE OSCAR LAMBRET   (France)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d INSERM   (France)

^e INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDONE DERIVATIVE; AMPHOLYTE; ANTINEOPLASTIC AGENT; C 1305; DIETHYL PYROCARBONATE; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); GUANINE; GYRASE INHIBITOR; TRIAZOLE; TRIAZOLE DERIVATIVE; TRIAZOLOACRIDONE; UNCLASSIFIED DRUG; ACRIDINE DERIVATIVE; DEOXYRIBONUCLEASE I; DRUG DERIVATIVE; ENZYME INHIBITOR; INTERCALATING AGENT; O,O DIETHYLPHOSPHORYLCHOLINE IODIDE; O,O-DIETHYLPHOSPHORYLCHOLINE IODIDE; PHOSPHORYLCHOLINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AT RICH SEQUENCE; CYTOTOXICITY; DNA STRUCTURE; DRUG DNA INTERACTION; DRUG SPECIFICITY; DRUG STRUCTURE; GC RICH SEQUENCE; IN VITRO STUDY; INTERCALATION COMPLEX; MOLECULAR MODEL; PRIORITY JOURNAL; PROTON TRANSPORT; STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE; CHEMISTRY; CIRCULAR DICHROISM; DNA FOOTPRINTING; DRUG ANTAGONISM; METABOLISM; SPECTROPHOTOMETRY;

ACRIDINES; ANTINEOPLASTIC AGENTS; CIRCULAR DICHROISM; DEOXYRIBONUCLEASE I; DNA; DNA FOOTPRINTING; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; ENZYME INHIBITORS; GUANINE; INTERCALATING AGENTS; MODELS, MOLECULAR; PHOSPHORYLCHOLINE; SPECTROPHOTOMETRY; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 27744455923     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gki904     Document Type: Article

References (45)

1. Cholody,W.M., Martelli,S. and Konopa,J. (1990) 8-Substituted 5-[(aminoalkyl)amino]-6H-v-triazolo[4,5,1-de]acridin-6-ones as potential antineoplastic agents. Synthesis and biological activity. J. Med. Chem., 33, 2852-2856.
2. Kusnierczyk,H., Cholody,W.M., Paradziej-Lukowicz,J., Radzikowski,C. and Konopa,J. (1994) Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones. Arch. Immunol. Ther. Exp. (Warsz.), 42, 415-423.
3. Lemke,K.,Poindessous,V.,Skladanowski,A. and Larsen, A.K.(2004) The antitumor triazoloacridone C-1305 is a topoisomerase II poison with unusual properties. Mol. Pharmacol., 66, 1035-1042.
4. Wesierska-Gadek,J., Schloffer,D., Gueorguieva,M., Uhl,M. and Skladanowski,A. (2004) Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest. Cancer Res., 64, 4487-4497.
5. Wang,J.C. (2002) Cellular roles of DNA topoisomerases: A molecular perspective. Nature Rev. Mol. Cell. Biol., 3, 430-440.
6. Wilstermann,A.M. and Osheroff,N. (2003) Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Curr. Top. Med. Chem., 3, 321-338.
7. Larsen,A.K., Escargueil,A.E. and Skladanowski,A. (2003) Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol. Ther., 99, 167-181.
8. Hande,K.R. (1998) Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim. Biophys. Acta., 1400, 173-84.
9. Larsen,A.K. and Skladanowski,A. (1998) Cellular resistance to topoisomerase-targeted drugs: From drug uptake to cell death. Biochim. Biophys. Acta., 1400, 257-274.
10. Larsen,A.K., Lemke,K., Oestergaard,V., Andersen,A.H., Vekris,A., Haaz,M.C., Robert,J., Escargueil,A.E. and Skladanowski,A. (2002) Topoisomerases and transcriptional regulation. Eur. J. Cancer, 38(suppl), S71.
11. Miassod,R., Razin,S.V. and Hancock,R. (1997) Distribution of topoisomerase II-mediated cleavage sites and relation to structural and functional landmarks in 830 kb of Drosophila DNA. Nucleic Acids Res., 25, 2041-2046.
12. Binaschi,M., Farinosi,R., Borgnetto,M.E. and Capranico,G. (2000) In vivo site specificity and human isoenzyme selectivity of two topoisomerase II-poisoning anthracyclines. Cancer Res., 60, 3770-3776.
13. Lovett,B.D., Strumberg,D., Blair,I.A., Pang,S., Burden,D.A., Megonigal,M.D., Rappaport,E.F., Rebbeck,T.R., Osheroff,N., Pommier,Y.G. et al. (2001) Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints. Biochemistry, 40, 1159-1170.
14. Collins,I., Weber,A. and Levens,D. (2001) Transcriptional consequences of topoisomerase inhibition. Mol. Cell. Biol., 21, 8437-8451.
15. Mondal,N. and Parvin,J.D. (2001) DNA topoisomerase IIalpha is required for RNA polymerase II transcription on chromatin templates. Nature, 413, 435-438.
16. Bailly,C., Helbecque,N., Hénichart,J.P., Colson,P., Houssier,C., Rao,K.E., Shea,R.G. and Lown,J.W. (1990) Molecular recognition between oligopeptides and nucleic acids. DNA sequence specificity and binding properties of an acridine-linked netropsin hybrid ligand. J. Mol. Recognit., 3, 26-35.
17. Colson,P., Bailly,C. and Houssier,C. (1996) Electric linear dichroism as a new tool to study sequence preference in drug binding to DNA. Biophys. Chem., 58, 125-140.
18. Bailly,C., Arafa,R.K., Tanious,F.A., Laine,W., Tardy,C., Lansiaux,A., Colson,P., Boykin,D.W. and Wilson,W.D. (2005) Molecular determinants for DNA minor groove recognition: Design of a bis-guanidinium derivative of ethidium that is highly selective for AT-rich DNA sequences. Biochemistry, 44, 1941-1952.
19. Bailly,C. and Waring,M.J. (1995) Comparison of different footprinting methodologies for detecting binding sites for a small ligand on DNA. J. Biomol. Struct. Dyn., 12, 869-898.
20. Bailly,C., Kluza,J., Martin,C., Ellis,T. and Waring,M.J. (2004) DNase I footprintng of small molecule binding sites on DNA. In Herdewijn,P. (ed.), Methods in Molecular Biology-Oligonucleotide Synthesis: Methods and Applications. Humana Press Inc., Totowa, NY, Vol. 288, pp. 319-342.
21. Bailly,C., Gentle,D., Hamy,F., Purcell,M. and Waring,M.J. (1994) Localized chemical reactivity in DNA associated with the sequence-specific bisintercalation of echinomycin. Biochem. J., 300, 165-73.
22. Bailly,C. and Waring,M.J. (1997) Diethylpyrocarbonate and osmium tetroxide as probes for drug-induced changes in DNA conformation in vitro. In Fox,K.R. (ed.), Drug-DNA Interaction Protocols. Humana Press, NJ, Vol. 90, pp. 51-79.
23. Ren,J. and Chaires,J.B. (1999) Sequence and structural selectivity of nucleic acid binding ligands. Biochemistry, 38, 16067-16075.
24. MacKerell,A.D.,Jr, Bashford,D., Bellott,M., Dunbrack,R.L.,Jr, Evanseck,J.D., Field,M.J., Fischer,S., Gao,J., Guo,H., Ha,S. et al. (1998) All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B., 102, 3586-3616.
25. Kalé,L., Skeel,R., Bhandarkar,M., Brunner,R., Gursoy,A., Krawetz,N., Phillips,J., Shinozaki,A., Varadarajan,K. and Schulten,K. (1999) NAMD2: Greater scalability for parallel molecular dynamics. J. Comput. Phys., 151, 283-312.
26. Hilal,S.H., Karickhoff,S.W. and Carreira,L.A. (2003) Verification and Validation of the SPARC Model. U.S. Environmental Protection Agency, Athens, GA, publication No. EPA/600/R-03/033.
27. Fogolari,F. and Tosatto,S.C. (2005) Application of MM/PBSA colony free energy to loop decoy discrimination: Towards correlation between energy and root mean square deviation. Protein Sci., 14, 889-901.
28. Fogolari,F., Moroni,E., Wojciechowski,M., Baginski,M., Ragona,L. and Molinari,H. (2005) MM/PBSA analysis of molecular dynamics simulations of bovine b-lactoglobulin: Free energy gradients in conformational transitions? Proteins, 59, 91-103.
29. Brooks,B.R., Bruccoleri,R.E., Olafson,B.D., States,D.J., Swaminathan,S. and Karplus,M. (1983) CHARMM: A program for macromolecular energy, minimization and dynamics calculations. J. Comput. Chem., 4, 187-217.
30. Madura,J.D., Briggs,J.M., Wade,R.C., Davis,M.E., Luty,B.A., Ilin,A., Antosiewicz,J., Gilson,M.K., Bagheri,B., Scott,L.R. et al. (1995) Electrostatics and diffusion of molecules in solution: Simulations with the University of Houston Brownian Dynamics Program. Comput. Phys. Commun., 91, 57-95.
31. Baker,N.A., Sept,D., Joseph,S., Holst,M.J. and McCammon,J.A. (2001) Electrostatics of nanosystems: Application to microtubules and the ribosome. Proc. Natl Acad. Sci. USA, 98, 10037-10041.
32. Humphrey,W., Dalke,A. and Schulten,K. (1996) VMD - Visual Molecular Dynamics. J. Mol. Graph., 14, 33-38.
33. Wilson,W.D., Tanious,F.A., Ding,D., Kumar,A., Boykin,D.W., Colson,P., Houssier,C. and Bailly,C. (1998) Nucleic acid interactions of unfused aromatic cations: Evaluation of proposed minor-groove, major-groove and intercalation binding modes. J. Am. Chem. Soc., 120, 10310-10321.
34. Bonjean,K., De Pauw-Gillet,M.C., Defresne,M.P., Colson,P., Houssier,C., Dassonneville,L., Bailly,C., Greimers,R., Wright,C., Quentin-Leclerq,J. et al. (1998) The DNA intercalating alkaloid cryptolepine interferes with topoisomerase II and inhibits primarily DNA synthesis in B16 melanoma cells. Biochemistry, 37, 5136-5146.
35. Fox,K.R. (1997) DNase I footprinting. In Fox,K.R. (ed.), Drug-DNA Interaction Protocols. Humana Press, NJ, Vol. 90, pp. 1-22.
36. Brown,P.M. and Fox,K.R. (1996) Minor groove binding ligands alter the rotational positioning of DNA fragments on nucleosome core particles. J. Mol. Biol., 262, 671-685.
37. Tse,W.C. and Boger,D.L. (2004) Sequence-selective DNA recognition: natural products and nature's lessons. Chem. Biol., 11, 1607-1617.
38. Boger,D.L., Ledeboer,M.W., Kume,M., Searcey,M. and Jin,Q. (1999) Total synthesis and comparative evaluation of luzopeptin A-C and quinoxapeptin A-C. J. Am. Chem. Soc., 121, 11375-11383.
39. Boger,D.L. and Saionz,K.W. (1999) DNA-binding properties of key sandramycin analogues: Systematic examination of the intercalation chromophore. Bioorg. Med. Chem., 7, 315-321.
40. Pelaprat,D., Delbarre,A., Le Guen,I., Roques,B.P. and Le Pecq,J.B. (1980) DNA intercalating compounds as potential antitumor agents. 2. Preparation and properties of 7H-pyridocarbazole dimers. J. Med. Chem., 23, 1336-143.
41. Shimada,T. and Guengerich,F.P. (1989) Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc. Natl Acad. Sci. USA, 86, 462-465.
42. Williamson,J.R. (1994) G-quartet structures in telomeric DNA. Annu. Rev. Biophys. Biomol. Struct., 23, 703-730.
43. Yoon,H.J., Choi,I.Y., Kang,M.R., Kim,S.S., Muller,M.T., Spitzner,J.R. and Chung,I.K. (1998) DNA topoisomerase II cleavage of telomeres in vitro and in vivo. Biochim. Biophys. Acta., 1395, 110-120.
44. Floridia,G., Zatterale,A., Zuffardi,O. and Tyler-Smith,C. (2000) Mapping of a human centromere onto the DNA by topoisomerase II cleavage. EMBO Rep., 1, 489-493.
45. Facompre,M., Carrasco,C., Colson,P., Houssier,C., Chisholm,J.D., Van Vranken,D.L. and Bailly,C. (2002) DNA-binding and topoisomerase I poisoning activities of novel disaccharide indolocarbazoles. Mol. Pharmacol., 62, 1215-1227.